Leprosy vaccine trial for healthy adults
Part of Infections clinical trials.
This trial tests a new vaccine (LEP-F1 + GLA-SE) to see if it is safe and helps the body fight leprosy. It is for healthy adults living in areas where leprosy is common.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are in good general health and do not have leprosy.
- You have not been infected with the leprosy germ before.
- You are not pregnant, not breastfeeding, and use birth control if you can get pregnant.
- You have had your primary COVID-19 vaccines at least 14 days before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
This Phase 2 trial tests whether adding metformin to standard leprosy treatment (multidrug therapy, or MDT) helps people with multibacillary leprosy recover better and remain tolerable over 48 weeks. Participants also get monitored closely for side effects and safety issues.
This study looks at certain genes (TGF beta 1) in people with leprosy who are already taking multidrug therapy. It aims to understand how these genes might affect the disease, which could lead to better treatments in the future.
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
This study tests a new tuberculosis vaccine called Lipovaxin in healthy adults aged 18–40. Researchers want to see if it is safe and how the body responds to it, which could help prevent TB infection in the future.
This study tests a new medicine called dovramilast for people with leprosy type 2 reaction, a painful inflammatory condition that can cause skin bumps and nerve problems. It compares the study drug to standard care to see if it is safe and effective.
Hear when a new Leprosy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.